NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disorders.
There is an urgent need to transform basic research discoveries into tools for treatment and prevention of mental illnesses. This article presents an overview of the National Institute of Mental Health (NIMH) programs and resources to address the challenges and opportunities in psychiatric drug development starting at the point of discovery through the early phases of translational research. We summarize NIMH and selected National Institutes of Health (NIH) efforts to stimulate translation of basic and clinical neuroscience findings into novel targets, models, compounds, and strategies for the development of innovative therapeutics for psychiatric disorders. Examples of collaborations and partnerships among NIMH/NIH, academia, and industry are highlighted.
Brady
Linda S
LS
Divison of Neuroscience and Basic Behavioral Science, National Institute of Mental Health, Bethesda, MD 20892, USA. lbrady@mail.nih.gov
Winsky
Lois
L
Goodman
Wayne
W
Oliveri
Mary Ellen
ME
Stover
Ellen
E
D000818:Animals; D002986:Clinical Trials as Topic; D055808:Drug Discovery / Q000379:methods; D004341:Drug Evaluation / Q000592:standards; D004345:Drug Industry; D006078:Government Programs; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000517:prevention & control; D009315:National Institute of Mental Health (U.S.); D009316:National Institutes of Health (U.S.); D055818:Public-Private Sector Partnerships; D012109:Research Support as Topic; D014481:United States; D014495:Universities
Am J Psychiatry. 2008 Feb;165(2):214-20
18172018
Schizophr Res. 2004 Dec 15;72(1):5-9
15531402
Schizophr Bull. 2007 Sep;33(5):1131-7
17630405
Nature. 2007 Aug 9;448(7154):645-6
17687303
Neuropsychopharmacology. 2008 Aug;33(9):2047
18626470
Bioorg Med Chem Lett. 2007 Nov 1;17(21):5783-9
17827006
Neuropsychopharmacology. 2008 Aug;33(9):2061-79
18046305
Neuropsychopharmacology. 2009 Jan;34(1):204-12
18830238
Neuropsychopharmacology. 2008 Aug;33(9):2048-60
18216778
Mol Cell Neurosci. 2008 Feb;37(2):187-95
18055216
Schizophr Bull. 2005 Jan;31(1):5-19
15888422
Biol Psychiatry. 2007 Dec 1;62(11):1324-33
17678633
Biol Psychiatry. 2007 Dec 15;62(12):1337-9
18054535
Neuropsychopharmacology. 2007 Nov;32(11):2360-8
17342171
J Biomol Screen. 2008 Feb;13(2):120-7
18216391
Nat Rev Drug Discov. 2007 Jul;6(7):521-32
17599084
Nat Rev Drug Discov. 2007 Mar;6(3):189-201
17330070
Science. 2004 Nov 12;306(5699):1138-9
15542455
Nat Rev Drug Discov. 2008 Feb;7(2):107-9
18246607
Bioorg Med Chem Lett. 2008 Feb 1;18(3):885-90
18178088
Am J Psychiatry. 2008 Feb;165(2):203-13
18172019
Neuropsychopharmacology. 2008 Aug;33(9):2080-92
18172433
J Physiol. 2008 Mar 15;586(6):1503-8
18202092
Schizophr Bull. 2006 Apr;32(2):214-9
16481659
Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5163-8
17360345
Trends Pharmacol Sci. 2007 Aug;28(8):390-6
17629962
JAMA. 2003 Mar 12;289(10):1278-87
12633190
Bioorg Med Chem Lett. 2008 Feb 15;18(4):1297-303
18243697
Nat Biotechnol. 2007 Mar;25(3):266
17344867
Annu Rep Med Chem. 2007;42:401-416
32287469
Schizophr Bull. 2007 Sep;33(5):1100-19
17617664
Mol Pharmacol. 2008 Apr;73(4):1213-24
18171729
J Pharmacol Exp Ther. 2007 Jan;320(1):1-13
16803859
Psychopharmacology (Berl). 2007 Mar;191(1):5-13
16718480
Mol Psychiatry. 2006 Jan;11(1):11-7
16355250
Mol Pharmacol. 2007 Jul;72(1):1-7
17405872
Schizophr Bull. 2007 May;33(3):805-22
16931542
Schizophr Bull. 2007 Sep;33(5):1093-9
17673495